Covalent Bioscience aims to develop first-in-class catalytic antibodies (Catabodies) and electrophilic vaccines (E-vaccines) for a range of unmet medical needs. Their lead catabodies focus on healthy aging and age-associated diseases. Their lead E-vaccine has promise for effective prophylaxis and therapy of HIV infection worldwide. Catalytic antibodies, also known as abzymes, are a unique class of antibodies that not only bind to their target antigen but also possess enzyme-like catalytic activity. In other words, they can accelerate specific chemical reactions, similar to the way enzymes do. Catalytic antibodies are a rare and naturally occurring phenomenon, but they can also be artificially generated using techniques such as immunization with transition-state analogs or phage display.